Last reviewed · How we verify
NCT03082768
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
EARLY_PHASE1 trial testing [18F]MNI-968 in Healthy Volunteers in 6 participants. Completed in 1 March 2018.
1 March 2018
Quick facts
| Lead sponsor | Molecular NeuroImaging |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 6 |
| Start date | 3 March 2017 |
| Primary completion | 1 March 2018 |
| Estimated completion | 1 March 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [18F]MNI-968 — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Molecular NeuroImaging — full company profile →
Who can join
Adults 18 to 50, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this protocol is to evaluate \[18F\]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03082768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [18F]MNI-968
Trials testing the same drug.
- NCT03142724 — Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Molecular NeuroImaging trials
Trials by the same sponsor.
- NCT03142724 — Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects · Phase 1 · completed
- NCT03058965 — Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain · EARLY_PHASE1 · completed
- NCT03876002 — Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03082768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Molecular NeuroImaging
- Last refreshed: 6 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03082768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing